SCHEMBL4764327

SCHEMBL4764327

COCCOCN(c1onc(C)c1C)S(=O)(=O)c1ccccc1-c1ccc(COS(C)(=O)=O)cc1C

nearest known ligand 0.41

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
EDNRA P25101 6/20 0.35
AGTR1 P30556 3/20 0.34
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536460 0.93 EDNRA (0.36) EDNRAAGTR1MAPT
SCHEMBL4764404 0.90 EDNRA (0.41) EDNRAAGTR1
SCHEMBL4774809 0.84 MAPT (0.34) EDNRAMAPT
SCHEMBL5531220 0.84 EDNRA (0.37) EDNRAAGTR1MAPT
SCHEMBL4774085 0.84 EDNRA (0.36) EDNRA
SCHEMBL30757402 0.83 EDNRA (0.43) EDNRAAGTR1MAPT
SCHEMBL26688926 0.83 EDNRA (0.43) EDNRAAGTR1MAPT
SCHEMBL4772907 0.83 EDNRA (0.35) EDNRAAGTR1
SCHEMBL4772899 0.82 EDNRA (0.42) EDNRAAGTR1
SCHEMBL4763990 0.82 EDNRA (0.40) EDNRAAGTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2002837-A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2008-12-17 EP disclosed
EP-1237888-B1 BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2006-09-13 EP disclosed
US-6852745-B2 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2005-02-08 US disclosed
US-6835741-B2 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists BRISTOL-MYERS SQUIBB COMPANY 2004-12-28 US disclosed
US-6638937-B2 As antihypertensive agents; for therapy of disorders related to renal, glomerular and mesangial cell function; therapy of endotoxemia or endotoxin shock as well as hemorrhagic shock; useful in alleviation of pain associated cancer BRISTOL-MYERS SQUIBB CO. 2003-10-28 US disclosed